Lv1
80 积分 2026-01-10 加入
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
12天前
已完结
Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going
13天前
已完结
Practical Guidance on [177Lu]Lu-PSMA-617 Treatment, Including Radiation Safety, Adverse Event Monitoring, and Patient Counseling
13天前
已完结
Rechallenge With 177Lu-PSMA Radioligand Therapy in Metastatic Castration-resistant and Hormone-sensitive Prostate Cancer: Lessons From a Multicase Experience
15天前
已完结
The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to (177)Lu-Prostate-Specific Membrane Antigen Therapy
17天前
已关闭
Neurologic Symptoms After (177)Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience
17天前
已完结
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
20天前
已完结
Clinical Impact and Dynamics of Clonal Hematopoiesis with 177Lu-PSMA-617 Therapy in Advanced Prostate Cancer
20天前
已关闭
Novel Therapeutic Strategies for Metastatic Prostate Cancer Care
21天前
已完结
Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review
21天前
已完结
皖公网安备34019202002308
